

**Joint working executive summary**

<b>Project title</b>	Yorkshire and Humber Academic Health Science Network (Y&H AHSN) Avoiding hypoglycaemia
<b>Partner organisation/s</b>	Yorkshire and Humber Academic Health Science Network (Y&H AHSN) and Sanofi Joint Working project
<b>Project rationale</b>	<p><i>The Avoiding Hypoglycaemia project is predicated fundamentally upon the aspiration that hypoglycaemia is wholly preventable, its avoidance clearly offering significant patient benefits both in terms of avoiding harm, together with the enabling of improved outcomes, ongoing confidence to self-manage and an enhanced quality of life overall.</i></p> <p><i>The project aims to support:</i></p> <ul style="list-style-type: none"> <li>• <i>Increased patient awareness of Hypoglycaemia signs and symptoms</i></li> <li>• <i>Better education around hypoglycaemia for patients, their carer's and their treating clinician</i></li> <li>• <i>Providing patients with better skills and knowledge to manage their own health and own care</i></li> <li>• <i>Better glycaemic control</i></li> <li>• <i>Increased engagement and more frequent discussions with a clinician for those patients with diabetes</i></li> <li>• <i>Evaluation of the toolkit – what impact does this have on the patient, the clinicians and the LHE including the ambulance service.</i></li> </ul> <p><i>In order to achieve the above aims Yorkshire and Humber Academic Health Science Network (Y&amp;H AHSN) and Sanofi are partnering in a Joint Working project. The project aims to implement the toolkit into clinical practice in primary care by integrating it in clinical systems across a minimum of two Clinical Commissioning Groups (CCGs). This will enable evaluation of the toolkit on patient outcomes along with the impact of the toolkit on ambulance call outs for hypoglycaemia. The joint working project will involve a balance of contributions with the pooling of skills, experience and resources from all parties involved. The overall project delivery will be overseen by a project manager.</i></p>
<b>Project period</b>	<i>Anticipated finish date for the project is Quarter 2 2020.</i>

<p><b>Project objectives</b></p>	<p><i>Intended Benefits</i></p> <p><i>For the Patient</i></p> <p><i>Patients might expect more equitable and consistent care as well as improved education around hypoglycaemia, better access to treatment options and improvement in clinical markers such as HbA1c.</i></p> <p><i>For the NHS</i></p> <p><i>Benefits to a participating CCG may include a high quality, more consistent approach to care, better identification of patients at risk of hypoglycaemia resulting in better health outcomes and better use of Healthcare and professional resources. It is expected that potential events requiring hospital admission that may be related to hypoglycaemia could be reduced.</i></p> <p><i>For Sanofi</i></p> <p><i>Sanofi may benefit by more patients treated appropriately with medicines from the Sanofi portfolio, better customer understanding and improved reputation.</i></p> <p><i>The results of the project will be written up and published to enable the learnings from the project to be shared.</i></p>
<p><b>Contact details</b></p>	<p><i>Y&amp;H AHSN:</i>  <i>Navigation Court Calder Park</i>  <i>Wakefield</i>  <i>WF2 7BJ</i>  <i>01924 664506</i></p> <p><i>Sanofi:</i>  <i>Fleur Chandler</i>  <i>Head of Market Access</i>  <i>Sanofi</i>  <i>410 Thames Valley Park Drive</i>  <i>Reading</i>  <i>Berks, RG6 1PT</i>  <a href="mailto:qb-marketaccess@sanofi.com"><i>qb-marketaccess@sanofi.com</i></a></p>